Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a prominent player in the neuroscience biopharmaceutical sector, is set to report its financial results for the fourth quarter and full year ending December 31, 2025, on February 19, 2026, prior to market opening. This announcement, made on February 9, 2026, also includes plans for a conference call and live webcast to discuss these results and provide a corporate update at 8:00 am ET the same day. Interested parties can access the conference call via a registration link or through the company’s website, where the live webcast will also be hosted on the Events & Presentations page.

In addition to the earnings announcement, Praxis management will participate in two upcoming investor conferences. The first is the Guggenheim Emerging Outlook: Biotech Summit 2026, where a corporate presentation will occur on February 11, 2026, at the Lotte New York Palace Hotel, New York City, at 1 pm ET. The second event is TD Cowen's 46th Annual Health Care Conference, scheduled for March 2, 2026, at the Boston Marriott Copley Place Hotel, with a presentation at 11:50 am ET. Both events will also offer live webcasts, and replays will be made available for approximately 90 days post-event.

Praxis is dedicated to translating genetic insights into therapeutic developments for CNS disorders characterized by neuronal imbalance, leveraging its proprietary platforms, Cerebrum™ for small molecules and Solidus™ for antisense oligonucleotides. With a robust pipeline that includes multiple late-stage product candidates, Praxis is well-positioned in the arena of neurological treatment. For further details, visit www.praxismedicines.com.

As Praxis Precision Medicines (NASDAQ: PRAX) prepares to release its fourth-quarter and full-year financial results for 2025 on February 19, 2026, market participants should approach the company’s stock with a keen interest. This report will likely provide critical insights into the company’s financial health and operational progress, particularly as it relates to its innovative CNS portfolio.

Given Praxis’ commitment to developing therapies targeting central nervous system disorders—an area that has attracted substantial investment and interest—investors will be closely watching how the company has advanced its clinical programs. With four late-stage product candidates in development, positive updates could drive the stock higher, aligning with broader trends in biotech sector performance. Conversely, any setbacks in clinical trials or disappointing financial results could exert downward pressure on shares.

Additionally, Praxis is set to present at two notable investor conferences in February and March: the Guggenheim Emerging Outlook: Biotech Summit and the TD Cowen 46th Annual Health Care Conference. These platforms can enhance the visibility of the company and its pipeline candidates to potential investors. Insights shared during these presentations may also influence market sentiment in the lead-up to the financial report. Attendees and investors should consider these conferences as opportunities to gauge management's confidence and strategic direction.

Investors should monitor key financial metrics in the upcoming report, including revenue growth, R&D spending, and upcoming catalysts, such as anticipated trial results. It’s advisable to maintain a balanced perspective—optimism based on the advancements in CNS therapies must be tempered with caution regarding the biotech industry's inherent volatility. As such, investors should keep an eye on the market reaction post-announcement and throughout the conference presentations, which could inform near-term trading strategies in PRAX stock.